The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia
Kathleen Morrisroe, Wendy Stevens, Joanne Sahhar, Gene-Slew Ngian, Nava Ferdowsi, Dylan Hansen, Shreeya Patel, Catherine L Hill, Janet Roddy, Jennifer Walker, Susanna Proudman, Mandana Nikpour
BMC Pulmonary Medicine | BMC | Published : 2019
BACKGROUND: To quantify the financial cost of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc). METHODS: Healthcare use was captured through data linkage, wherein clinical data for SSc patients enrolled in the Australian Scleroderma Cohort Study were linked with hospital, emergency department (ED) and ambulatory care databases (MBS) for the period 2008-2015. PAH was diagnosed on right heart catheter according to international criteria. Determinants of healthcare cost were estimated using logistic regression. RESULTS: Total median (25th-75th) healthcare cost per patient (including hospital, ED and MBS cost but excluding medication cost) for our cohort during 2008-2015 was AUD..View full abstract
Awarded by National Health and Medical Research Council of Australia
This ASCS database is funded by Scleroderma Australia, Arthritis Australia, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia and Pfizer. These companies had no input in this study design, data collection, data analysis, data interpretation or manuscript preparation. KM was supported by Arthritis Australia Fellowship. MN holds a National Health and Medical Research Council of Australia Career Development Fellowship (APP 1126370).